𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials

✍ Scribed by Ira Katz; Peter-Paul de Deyn; Jacobo Mintzer; Andrew Greenspan; Young Zhu; Henry Brodaty

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
167 KB
Volume
22
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Dementia typically includes behavioral and psychological symptoms of dementia (BPSD) as well as cognitive decline. Psychosis of Alzheimer's disease (AD) is a specific component of AD, characterized by delusions, misidentifications, and hallucinations.

Methods

This study is a meta‐analysis of patients with psychosis of AD from four large placebo‐controlled clinical trials of risperidone in dementia. Three trials included patients diagnosed with heterogeneous symptoms of BPSD (those with psychosis of AD were included in this analysis), while one trial included only those diagnosed with psychosis of AD. Efficacy was measured using the Behavioral Pathology in Alzheimer's Disease (BEHAVE‐AD) Psychosis subscale and Clinical Global Impression (CGI).

Results

Primary analyses in the psychosis of AD population demonstrated that risperidone significantly improved scores on the BEHAVE‐AD Psychosis subscale and CGI scale compared with placebo. Secondary analyses demonstrated that patients with more severe symptoms showed a more pronounced response to treatment with risperidone compared with placebo than those patients with less severe symptoms. Extrapyramidal symptoms and somnolence were more frequent with risperidone than placebo (p = 0.04). Cerebrovascular adverse events and all‐cause mortality were observed more frequently, although not statistically significantly, with risperidone versus placebo.

Conclusions

This meta‐analysis of psychosis of AD showed improvement in psychotic symptoms and general clinical improvement in patients with psychosis of AD treated with risperidone compared with placebo. The benefits of treatment were most significant in patients with severe symptoms. The safety profile of risperidone in this psychosis of AD population was similar to the more general BPSD population. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Risperidone for psychosis of Alzheimer's
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial
✍ Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Cl 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of alzheimer's disease (ad) and mixed dementia (md) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidon

Efficacy and safety of leflunomide in th
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial
✍ J. Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F. Rosen; Frank Behrens; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views

## Abstract ## Objective Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. We undertook this double‐blind,

A randomized, placebo-controlled study o
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil
✍ Sanford I. Finkel; Jacobo E. Mintzer; Maurice Dysken; K. R. R. Krishnan; Tal Bur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

## Abstract ## Objective To examine the safety and efficacy of sertraline augmentation therapy in the treatment of behavioral manifestations of Alzheimer's disease (AD) in outpatients treated with donepezil. ## Methods and materials Patients with probable or possible AD, and a Neuropsychiatric I

Safety and tolerability of duloxetine in
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials
✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random